A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD)

ND Toussaint, E Pedagogos, NM Lioufas… - Journal of the …, 2020 - journals.lww.com
Background Hyperphosphatemia is associated with increased fibroblast growth factor 23
(FGF23), arterial calcification, and cardiovascular mortality. Effects of phosphate-lowering …
被引用次数：66 相关文章

A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)

ND Toussaint, E Pedagogos, NM Lioufas, GJ Elder… - 2020 - pubmed.ncbi.nlm.nih.gov
Background Hyperphosphatemia is associated with increased fibroblast growth factor 23
(FGF23), arterial calcification, and cardiovascular mortality. Effects of phosphate-lowering …

A randomized trial on the effect of phosphate reduction on vascular end points in CKD (improve-CKD)

ND Toussaint, E Pedagogos… - Journal of the …, 2020 - research.bond.edu.au
Background Hyperphosphatemia is associated with increased fibroblast growth factor 23
(FGF23), arterial calcification, and cardiovascular mortality. Effects of phosphate-lowering …

A randomized trial on the effect of phosphate reduction on vascular end points in CKD (improve-CKD)

ND Toussaint, E Pedagogos, NM Lioufas, GJ Elder… - 2020 - hekyll.services.adelaide.edu.au
BACKGROUND: Hyperphosphatemia is associated with increased fibroblast growth factor
23 (FGF23), arterial calcification, and cardiovascular mortality. Effects of phosphate-lowering …

A randomized trial on the effect of phosphate reduction on vascular end points in CKD (improve-CKD)

ND Toussaint, E Pedagogos… - Journal of the …, 2020 - research.monash.edu
Background Hyperphosphatemia is associated with increased fibroblast growth factor 23
(FGF23), arterial calcification, and cardiovascular mortality. Effects of phosphate-lowering …
[HTML] nih.gov

[HTML][HTML] A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)

ND Toussaint, E Pedagogos, NM Lioufas… - Journal of the …, 2020 - ncbi.nlm.nih.gov
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)
- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

A randomized trial on the effect of phosphate reduction on vascular end points in CKD (improve-CKD)

IMPROVE-CKD Trial … - Journal of the …, 2020 - research-repository.uwa.edu.au
Background Hyperphosphatemia is associated with increased fibroblast growth factor 23
(FGF23), arterial calcification, and cardiovascular mortality. Effects of phosphate-lowering …

A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)

ND Toussaint, E Pedagogos… - Journal of the …, 2020 - mymedr.afpm.org.my
BACKGROUND: Hyperphosphatemia is associated with increased fibroblast growth factor
23 (FGF23), arterial calcification, and cardiovascular mortality. Effects of phosphate-lowering …

[引用][C] A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD)

ND Toussaint, E Pedagogos… - Journal of the …, 2020 - espace.library.uq.edu.au
Background Hyperphosphatemia is associated with increased fibroblast growth factor 23
(FGF23), arterial calcification, and cardiovascular mortality. Effects of phosphate-lowering …

A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)

ND Toussaint, E Pedagogos, NM Lioufas… - Journal of the American …, 2020 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background</jats: title>< jats: p> Hyperphosphatemia is
associated with increased fibroblast growth factor 23 (FGF23), arterial calcification, and …